Exploration of Medicine (Apr 2023)

Mechanistic approaching study in COVID-19 patients treated with high doses of vitamin D

  • Mauro G. Silva,
  • Felipe Inserra,
  • Javier Mariani,
  • Laura Antonietti,
  • Myriam Nuñez,
  • Carlos Tajer,
  • León Ferder,
  • Pablo I. F. Inserra,
  • Fernando Ross,
  • Milagro Sánchez Cunto,
  • Magalí Bertelli,
  • Gabriela de Larrañaga,
  • Eliana M. Cela,
  • Daniel H. González Maglio,
  • Mariela M. Gironacci,
  • Walter Manucha

DOI
https://doi.org/10.37349/emed.2023.00137
Journal volume & issue
Vol. 4, no. 2
pp. 246 – 253

Abstract

Read online

Aim: To evaluate angiotensin II (Ang II) and Ang-(1-7) levels and the cytokine profile in patients hospitalized with mild coronavirus disease 2019 (COVID-19) and contrast them with patients with identical clinical conditions but treated with high doses of vitamin D (vitD). Methods: From the 218 patients recruited (ClinicalTrials.gov NCT04411446), 16 participated in this sub-study and were randomized to a single oral dose of 500,000 IU vitD (n = 10) or placebo (n = 6). Plasmatic Ang II and Ang-(1-7) levels were determined by radioimmunoassay and interleukins (ILs) 1, 6, 8, and 10 and tumor necrosis factor alpha (TNF-α) by enzyme-linked immunosorbent assay before and after treatment. Parallel, serum 25-hydroxyvitamin D3 (25-OH vitD) concentrations as vitD status was measured by a chemiluminescence immunoassay. Results: A trend towards an increase in Ang-(1-7) and a decrease in Ang II levels were observed in placebo- and vitD-treated COVID-19 patients compared to baseline values. There was no difference in Ang II and Ang-(1-7) levels between placebo- and vitD-treated COVID-19 patients. Similar results were obtained with ILs profile. COVID-19 patients showed an increase in the protective component of the RAS which was not improved by vitD treatment. Conclusions: VitD did not improve RAS disbalance in COVID-19. Notwithstanding, the authors visualize that acute treatment with high doses of vitD may show a trend to a decline in inflammatory ILs and an increase in protective markers. Finally, the authors would like to highlight the limitations of this preliminary study, namely the small number of patients and the use of a large single bolus dose of vitD rather than lower daily doses for extended periods with prolonged follow-up times. All these factors need special consideration in the designs of new vitD supplementation trials. All these factors need special consideration in the designs of new vitD supplementation trials (ClinicalTrials.gov identifier: NCT04411446).

Keywords